NBTXR3 First in Class Radioenhancer
Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.
Only one administration
Fits into existing standard of care:
One product addressing areas of high unmet medical needs.
See moreRecent Press Releases
Nanobiotix Provides Corporate Update and Highlights Key 2022 Milestone Targets
Nanobiotix Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
ALL NANOBIOTIX PRESS RELEASES
Events
Meet Nanobiotix International events and conferences
JOIN US
“Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”
Anne-Juliette Hermant
Chief People Officer